Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Neuroimmunology and Emerging Therapeutics in Atopic Dermatitis and Itch
Description
The speaker reviewed neuroimmunology in atopic dermatitis and itch, emphasizing how barrier damage triggers “alarm” cytokines such as IL-33 and TSLP, which recruit innate immune cells and signal to sensory neurons through pathways involving JAKs. They highlighted how dupilumab transformed treatment and helped establish the idea that cytokines can directly modulate itch through the nervous system, not just inflammation. The talk focused on IL-31 as a key pruritogen and on nemolizumab, an IL-31 receptor blocker, noting its strong anti-itch effects but also the possibility of paradoxical immune effects because IL-31 receptor biology differs in immune cells versus neurons. Emerging therapies were discussed, including ligand-targeting IL-31 nanobody approaches, JAK1 inhibitors such as abrocitinib and ruxolitinib, KLK5/7 antibody strategies aimed at serine protease pathways linked to barrier dysfunction, and IL-18 blockade as a novel treatment avenue. Overall, the speaker argued that atopic dermatitis and itch arise from multiple interconnected pathways involving barrier proteins, cytokines, sensory nerves, and proteases, and that these insights are driving new therapeutics and biomarker development.
View moreConclusions
- Atopic dermatitis and itch are driven by multiple interconnected pathways rather than a single dominant mechanism.
- Barrier stress and damage initiate alarmin release, especially IL-33, TSLP, and IL-18, which amplify type 2 inflammation and itch signaling.
- Sensory neurons are direct targets of type 2 cytokines, making itch a neuroimmune process as much as an immune one.
- Dupilumab and other type 2 blockade therapies can meaningfully improve itch, and real-world observations suggest they may help in chronic pruritus of unknown origin.
- IL-31 is a key pruritogenic cytokine, and blocking IL-31R with nemolizumab can substantially reduce itch.
- IL-31 receptor blockade may have unexpected immunologic consequences, including paradoxical inflammatory skin eruptions, even while it suppresses itch.
- Next-generation IL-31-targeting strategies that bind the ligand directly may preserve anti-itch efficacy while avoiding receptor-sequestration effects.
- JAK1 is enriched in itch-receptive sensory neurons, supporting the strong anti-pruritic effects of JAK inhibitors in atopic dermatitis.
- Kallikreins, especially KLK7, appear to be important disease amplifiers and promising therapeutic targets in atopic dermatitis.
- Type 2 cytokines can induce KLK7, linking inflammatory signaling to protease-driven itch and barrier dysfunction.
- Antibody-based inhibition of KLK5/7 can reduce keratinocyte proliferation and may represent a viable new treatment approach.
- IL-18 emerges as an additional biomarker and therapeutic target in atopic dermatitis, with early clinical data suggesting benefit from IL-18 binding therapy.
- Overall, the study argues that precision targeting of distinct immune, neuronal, and barrier pathways will likely produce the next wave of more effective itch and atopic dermatitis treatments.
- Kim et al. Sci Transl Med 2013
- Kim et al. J Immunol 2014
- Oetjen et al. Cell 2017
- Jeon et al. J Dermatol Treat 2021
- Cevikbas et al. JACI 2013
- Kabashima et al. NEJM 2020
- Stander et al. NEJM 2020
- Kim JACI 2024
- Prassas et al. Nat Rev Drug Disc 2015
- Komatsu et al. Exp Dermatol 2007
- Guo et al. JID 2020
- Morizane et al. JACI 2012
- Ny et al. Acta Derm Venereol 2003
- Mack et al. Sci Transl Med 2020
- Oetjen et al. Nat Neurosci 2015
- Usoskin et al. Nat Neurosci 2015